The company said its nebulizer treatment produced a 79% lower risk of patients developing severe disease than those given a placebo in initial trials.
The company said its nebulizer treatment produced a 79% lower risk of patients developing severe disease than those given a placebo in initial trials, and patients that received the treatment "were more than twice as likely to recover over the course of the treatment period compared to those receiving placebo," Synairgen claimed.
The drug, SNG001, is a formulation of a naturally-occurring antiviral protein called interferon beta inhaled directly into the lungs, in the hope of stimulating an immune response. The treatment is aimed at preventing infected patients deteriorating from requiring oxygen to being placed on a ventilator.
"Our efforts are now focused on working with the regulators and other key groups to progress this potential Covid-19 treatment as rapidly as possible."
Could signal. lol.
Won't matter much in the end, investors!
I thought we save vaccine news for red days?
could, would, should just adds to fake news and do nothing to help. Report the did, done, approved, safe.
TheDiamondBoy10
The smaller the trial, the bigger the breakthru ... hmmm ... OK ...
Just before market open! What a surprise
Amazing!! Stock up 3.5x already on market opening 🙊
Every disease ever was cured before a phase 3 trial was sucessful
Who needs stimulus when you have vaccine pumps?
WeDontCare
Need P3 placebo-controlled studies (determine if double-blinding maintained), if not remdesivir control - UK pharma claims small clin study of respiratory nebulizer treatment for coronavirus vs placebo lowered risk 79% of developing severe disease (N=101) s
Read this
Market manipulation at its finest, new week same old bullshit headlines.